EGFR and lung carcinoma: Manifestation of secondary mutations such as T790M and C797S, stimulation of another signaling pathway like Met, downstream pathway deviation like AKT mutations, and EGFR-TKIs-mediated apoptotic pathway disruption are the mechanisms that make lung cancer cells resistant to TKIs (109).